What is Alzheimer's Disease?
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases, and its incidence increases rapidly with age. With the intensification of societal aging, this disease may bring about increasingly severe social burdens.
In individuals affected by Alzheimer's, the aggregation of these toxic proteins leads to the formation of plaques and tangles within the brain. These abnormal structures disrupt neural communication, induce cellular damage, and subsequently result in cognitive decline and memory impairment, hallmarks of the disease.
ALZHIMER’S HAS NO CURE
Globally, there is a new dementia patient every 3 seconds. With the exacerbation of aging population, the number of Alzheimer's patients is increasing. It is estimated that by 2050, the number of Alzheimer's dementia patients in Asia will reach 25 million, meaning there will be 2 Alzheimer's patients among every 100 individuals. Alzheimer's disease also exhibits a trend toward younger onset. Data released as early as 2015 indicated that the onset age of dementia has shifted from the formerly recognized age of 65 to 55.
Currently, only six drugs have received FDA approval for market use globally: Tacrine approved in 1993, Donepezil in 1996, Rivastigmine in 2000, Galantamine in 2001, Memantine hydrochloride in 2003, and Memantine in 2014. However, all these drugs are symptomatic treatments, and none can treat Alzheimer's disease itself. Therefore, after being diagnosed with AD, there is no cure or reversal from drug intake as of now. All we can do is, based on existing research, try to prevent ourselves from falling prey to this gentle but fatal illness.
Currently, only six drugs have received FDA approval for market use globally: Tacrine approved in 1993, Donepezil in 1996, Rivastigmine in 2000, Galantamine in 2001, Memantine hydrochloride in 2003, and Memantine in 2014. However, all these drugs are symptomatic treatments, and none can treat Alzheimer's disease itself. Therefore, after being diagnosed with AD, there is no cure or reversal. All we can do is, based on existing research, try to prevent ourselves from falling prey to this gentle but fatal illness.
REWIRING THE BRAIN- THE NEXT FRONTIER OF SUPERMIRCOSURGERY-a PRS REVIEW
Dr. Qingping Xie:
Inventor and expert on Deep cervical LVA supermicrosurgery method for AD disease
Prof. QINGPING XIE is an expert microsurgeon at Hangzhou qiushi hosptial Hangzhou, China. He obtained his MD from the Second Military Medical University in Shanghai in 1989 and formerly served as the Director of the Hand Surgery Department, Peripheral Nerve Diagnostic and Therapeutic Center, Sino-Japanese Artificial Finger Joint Transplantation Training Center, and the International Rheumatoid Arthritis Joint Diagnosis and Treatment Center at Zhejiang People's Hospital. Presently, he holds the positions of President at Hangzhou Qiushi Hospital, President at Hangzhou Huagong Hospital, and Honorary President at Hangzhou Plastic Surgery Hospital.
s such as microsurgery, hand surgery, rehabilitation medicine, and reconstructive surgery. Additionally, Prof Qingping Xie holds a certain level of influence and standing in the medical community both domestically and internationally.
Scientific collaboration
with
Beijing Tiantan
Hospital （北京天坛医院）
About Hangzhou qiushi hosptial
Hangzhou Qiushi Hospital is a leading private, multidisciplinary hospital pioneering research in geriatric diseases including deep cervical LVA supermicrosurgical methods for brain functional disorders such as Alzheimer's disease, Parkinson's disease, tinnitus, and amyotrophic lateral sclerosis (ALS). They are keen to academic collaboration with renowned international and domestic partners in the field of surgical treatment for brain functional disorders.